Sarah H. Youssef

Sarah H. Youssef

Auto-generated profile, based on publicly available information

Sarah H. Youssef

Department of Pharmaceutical Services Children's Cancer Hospital Egypt Cairo Egypt

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2021 in Blood
Verified
Journal Article
Open access
PDF file
ISIman Sidhom
Iman Sidhom
KSKhaled Shaaban
Khaled Shaaban
SYSarah H. Youssef
Sarah H. Youssef
NANesreen Ali
Nesreen Ali
SGSeham Gohar
Seham Gohar
GRGaston K. Rivera
Gaston K. Rivera
Legacy data show that ∼40% of children with acute lymphoblastic leukemia (ALL) were cured with limited antimetabolite-based chemotherapy regimens. However, identifying patients with very-low-risk (VLR) ALL remains imprecise. Patients selected based on a combination of presenting features and a minimal residual disease (MRD) level <0.01% on day 19 of induction therapy had excellent outcomes with low-intensity treatment. We investigated the impact of MRD levels between 0.001% and <0.01% early in remission induction on the outcome of VLR ALL treated with a low-intensity regimen. Between October of 2011 and September of 2015, 200 consecutive patients with B-precursor ALL with favorable clinicopathologic features and MRD levels <0.01%, as assessed by flow cytometry in the bone marrow on day 19 and at the end of induction therapy, received reduced-intensity therapy. The 5-year event-free survival was 89.5% (± 2.2% standard error [SE]), and the overall survival was 95.5% (± 1.5% SE). The 5-year cumulative incidence of relapse (CIR) was 7% (95% confidence interval, 4-11%). MRD levels were between 0.001% and <0.01% on day 19 in 29 patients. These patients had a 5-year CIR that was significantly higher than that of patients with undetectable residual leukemia (17.2% ± 7.2% vs 5.3% ± 1.7%, respectively; P = .02). Our study shows that children with VLR ALL can be treated successfully with decreased-intensity therapy, and it suggests that the classification criteria for VLR can be further refined by using a more sensitive MRD assay.

22 April 2022 in Science Advances
Verified
Journal Article
Open access
VBValentin Barsan
Valentin Barsan
YXYuntao Xia
Yuntao Xia
DKDavid Klein
David Klein
VGVeronica Gonzalez-Pena
Veronica Gonzalez-Pena
SYSarah Youssef
Sarah Youssef
CGCharles Gawad
Charles Gawad
Treatment of acute lymphoblastic leukemia (ALL) necessitates continuous risk assessment of leukemic disease burden and infections that arise in the setting of immunosuppression. This study was performed to assess the feasibility of a hybrid capture next-generation sequencing panel to longitudinally measure molecular leukemic disease clearance and microbial species abundance in 20 pediatric patients with ALL throughout induction chemotherapy. This proof of concept helps establish a technical and conceptual framework that we anticipate will be expanded and applied to additional patients with leukemia, as well as extended to additional cancer types. Molecular monitoring can help accelerate the attainment of insights into the temporal biology of host-microbe-leukemia interactions, including how those changes correlate with and alter anticancer therapy efficacy. We also anticipate that fewer invasive bone marrow examinations will be required, as these methods improve with standardization and are validated for clinical use.

27 February 2025 in Hematological Oncology
Verified
Journal Article
Closed access
HBHala Bekhit
Hala Bekhit
LELouay Eldeeb
Louay Eldeeb
EMEmad Moussa
Emad Moussa
SYSarah H. Youssef
Sarah H. Youssef
NANesreen Ali
Nesreen Ali